KaydedilenlerDerginizi ekleyin

Dergiler / Haydarpaşa Numune Medical Journal / 2021 / Cilt: 61 - Sayı: 2

Computed Tomography Prediction of Resectability of Pancreatic Adenocarcinoma Using National Comprehensive Cancer Network Criteria

İsmail Ege SUBAŞI
Levent SOYDAN
Mehmet TORUN
Ceren Karabiber DEVECİ
Turgay ÖNER
Kamil CANPOLAT
Umut KINA
Sayfa
189–196
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: We evaluated the diagnostic accuracy of computed tomography (CT) in determining resectability of pancre- atic adenocarcinoma using National Comprehensive Cancer Network (NCCN) Criteria.
📊
Temel Bulgular & Veri:Methods: Two radiologists retrospectively reviewed abdominal CT images from 36 patients with non-metastatic pancreatic adenocarcinoma who were operated on between 2018 and 20120.
💡
Sonuç & Katkı:Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: We evaluated the diagnostic accuracy of computed tomography (CT) in determining resectability of pancre- atic adenocarcinoma using National Comprehensive Cancer Network (NCCN) Criteria. Methods: Two radiologists retrospectively reviewed abdominal CT images from 36 patients with non-metastatic pancreatic adenocarcinoma who were operated on between 2018 and 20120. Based on CT findings six patients were reported as resectable, seven patients as borderline resectable, and 23 patients as unresectable using NCCN criteria for resectability. Positive predictive values for negative resection margin (R0) were assessed for CT using post-operative histopathological reports as reference standards. Results: In 36 patients who preceded to surgery R0 resection rates were 83% (5 of 6), 71% (5 of 7), and 60% (14 of 23) for resectable, borderline resectable, and unresectable disease, respectively (p

🔖

Bu Makaleye Atıf Yap

SUBAŞI, İ. E., SOYDAN, L., TORUN, M., DEVECİ, C. K., ÖNER, T., CANPOLAT, K., KINA, U. (2022). Computed Tomography Prediction of Resectability of Pancreatic Adenocarcinoma Using National Comprehensive Cancer Network Criteria. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 2, 189–196. https://ajindex.com/articles/535934

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of inci- dence and mortality worldwide for 36 cancers in 185 coun- tries. CA Cancer J Clin 2018;68:394–424
  2. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pan- creatic cancer. Ann Surg 2007;246:173–80
  3. Gnerlich JL, Luka SR, Deshpande AD, Dubray BJ, Weir JS, Car- penter DH, et al. Microscopic margins and patterns of treat- ment failure in resected pancreatic adenocarcinoma. Arch Surg 2012;147:753–60
  4. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor deter- mining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586–94
  5. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg 2011;254:311–9
  6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049–57
  7. Callery MP, Chang KJ, Fishman EK, Talamonti MS, Traverso LW, Linehan DC. Pretreatment assessment of resectable and bor- derline resectable pancreatic cancer: Expert consensus state- ment. Ann Surg Oncol 2009;16:1727–33
  8. Tempero MA. NCCN guidelines updates: Pancreatic cancer. J Natl Compr Canc Netw 2019;17:603–5
  9. Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC can- cer staging manual: Pancreas and hepatobiliary cancers. Ann Surg Oncol 2018;25:845–7
  10. Pathologists TRCo. Standards and datasets for reporting can- cers. In: Dataset for Histo-Pathological Reporting of Carcino- mas of the Pancreas, Ampulla of Vater and Common Bile Duct. 2nd ed. London, England: The Royal College of Pathologists; 2017
  11. Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic duc- tal adenocarcinoma: Definition and consensus of the inter- national study group for pancreatic surgery (ISGPS). Surgery 2014;156:1–14
  12. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with folfirinox in combination with losartan followed by chemoradiotherapy for locally ad- vanced pancreatic cancer: A phase 2 clinical trial. JAMA Oncol 2019;5:1020–7
  13. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;33:1770–8
  14. Zamboni GA, Kruskal JB, Vollmer CM, Bapti